[Evolution of chronic myeloid leukemia on nilotinib after failure of imatinib].
作者信息
Sawadogo Salifo, Hien Francis Michel, Ouédraogo Macaire Sampawendé, Drabo Youssouf Joseph
机构信息
Laboratoire d'hématologie et d'immunologie du Centre hospitalier universitaire Sourô Sanou, 01 BP 676 Bobo-Dioulasso 01 Burkina Faso.
Service de médecine interne, Centre hospitalier universitaire Sourô Sanou, 01 BP 676 Bobo-Dioulasso Burkina Faso.
出版信息
Pan Afr Med J. 2014 Jun 17;18:142. doi: 10.11604/pamj.2014.18.142.3308. eCollection 2014.
Abstract
摘要
相似文献
1
[Evolution of chronic myeloid leukemia on nilotinib after failure of imatinib].伊马替尼治疗失败后慢性髓性白血病患者使用尼罗替尼的病情演变
Pan Afr Med J. 2014 Jun 17;18:142. doi: 10.11604/pamj.2014.18.142.3308. eCollection 2014.
2
[Nilotinib in patients with chronic myeloid leukemia without response to imatinib].[尼洛替尼用于对伊马替尼无反应的慢性髓性白血病患者]
Rev Med Inst Mex Seguro Soc. 2014 May-Jun;52(3):330-3.
3
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.尼罗替尼（原AMN107）是一种高度选择性的BCR-ABL酪氨酸激酶抑制剂，对伊马替尼耐药和不耐受的慢性期费城染色体阳性慢性髓性白血病患者有效。
Blood. 2007 Nov 15;110(10):3540-6. doi: 10.1182/blood-2007-03-080689. Epub 2007 Aug 22.
4
[Particular evolution of complex cytogenetic variants of chronic myeloid leukemia treated with imatinib].[伊马替尼治疗慢性髓性白血病复杂细胞遗传学变异的特殊演变]
Pan Afr Med J. 2013 Aug 11;15:132. doi: 10.11604/pamj.2013.15.132.2207. eCollection 2013.
5
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.一线尼洛替尼或伊马替尼治疗的慢性期慢性髓性白血病患者的早期分子反应可预测其结局。
Blood. 2014 Feb 27;123(9):1353-60. doi: 10.1182/blood-2013-06-510396. Epub 2013 Dec 11.
6
Why doesn't imatinib cure chronic myeloid leukemia?伊马替尼为什么不能治愈慢性髓性白血病？
Oncologist. 2010;15(2):182-6. doi: 10.1634/theoncologist.2009-0297. Epub 2010 Feb 2.
7
Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?端粒酶在慢性期慢性髓性白血病、疾病进展和伊马替尼耐药中起作用吗？
Leuk Lymphoma. 2008 Jun;49(6):1022-3. doi: 10.1080/10428190802074635.
8
Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.在三家不同医院接受治疗的慢性髓性白血病患者中，达沙替尼在伊马替尼治疗失败或不耐受后的疗效和耐受性与正规临床试验所取得的结果相当。
Leuk Lymphoma. 2013 Oct;54(10):2310-3. doi: 10.3109/10428194.2013.772173. Epub 2013 Feb 28.
9
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy.伊马替尼治疗失败后接受尼洛替尼治疗的慢性髓性白血病患者费城阴性造血中克隆性染色体异常的出现。
Leuk Res. 2009 Dec;33(12):e218-20. doi: 10.1016/j.leukres.2009.05.010. Epub 2009 Jun 13.
10
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.尼洛替尼治疗伊马替尼耐药/不耐受的 Ph+ 慢性髓性白血病慢性期患者结局预测。
Leukemia. 2013 Apr;27(4):907-13. doi: 10.1038/leu.2012.305. Epub 2012 Nov 6.
本文引用的文献
1
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.皮下注射奥马曲拉治疗既往接受过包括伊马替尼在内的 2 种或以上酪氨酸激酶抑制剂治疗的慢性期慢性髓性白血病患者。
Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):584-91. doi: 10.1016/j.clml.2013.03.020. Epub 2013 Jun 17.
2
Management of imatinib-resistant patients with chronic myeloid leukemia.伊马替尼耐药的慢性髓性白血病患者的管理。
Ther Adv Hematol. 2013 Apr;4(2):103-17. doi: 10.1177/2040620712468289.
3
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.尼洛替尼与伊马替尼相比，可降低新诊断的慢性期慢性髓性白血病患者的 BCR-ABL 突变发生率。
Blood. 2013 May 2;121(18):3703-8. doi: 10.1182/blood-2012-04-423418. Epub 2013 Mar 15.
4
Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy.第二代酪氨酸激酶抑制剂：一线 CML 治疗的未来。
Clin Cancer Res. 2011 Apr 1;17(7):1674-83. doi: 10.1158/1078-0432.CCR-10-2922. Epub 2011 Feb 9.
5
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.尼洛替尼治疗伊马替尼耐药或不耐受的慢性期慢性髓性白血病患者有效：24 个月随访结果。
Blood. 2011 Jan 27;117(4):1141-5. doi: 10.1182/blood-2010-03-277152. Epub 2010 Nov 22.
6
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.慢性髓性白血病：欧洲白血病网络概念与管理建议的更新
J Clin Oncol. 2009 Dec 10;27(35):6041-51. doi: 10.1200/JCO.2009.25.0779. Epub 2009 Nov 2.
7
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.在两种先前的酪氨酸激酶抑制剂治疗失败后使用尼罗替尼或达沙替尼：长期随访
Blood. 2009 Nov 12;114(20):4361-8. doi: 10.1182/blood-2009-05-221531. Epub 2009 Sep 3.
8
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.慢性髓系白血病管理的不断演变的概念：代表欧洲白血病网的专家小组的建议
Blood. 2006 Sep 15;108(6):1809-20. doi: 10.1182/blood-2006-02-005686. Epub 2006 May 18.
Zotero 插件